Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2019 Sep 13;25(12):2522–2526. doi: 10.1016/j.bbmt.2019.09.012

Figure 1.

Figure 1.

Relative mortality among survivors post-AHCT in patients with DLBCL compared to age-, gender-, and race-matched US healthy population. (A) SMR for 1-year survivors was 4.0 (95% CI, 3.2–5.1). (B) SMR for 2-year survivors was 3.0 (95% CI, 2.2–4.0). (C) SMR for 3-year survivors was 2.4 (95% CI, 1.7–3.4). (D) SMR for 5-year survivors was 1.8 (95% CI, 1.1–2.9).